Kenneth A Jacobson

List of Publications by Citations

742 papers	35,373 citations	85 h-index	147 g-index
816 ext. papers	38,537 ext. citations	6 avg, IF	7.29 L-index

#	Paper	IF	Citations
742	Adenosine receptors as therapeutic targets. *Nature Reviews Drug Discovery*, **2006**, 5, 247-64	64.1	1040
741	International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. *Pharmacological Reviews*, **2006**, 58, 281-341	22.5	996
740	International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. *Pharmacological Reviews*, **2011**, 63, 1-34	22.5	948
739	Structure of an agonist-bound human A2A adenosine receptor. *Science*, **2011**, 332, 322-7	33.3	706
738	UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. *Nature*, **2007**, 446, 1091-5	50.4	566
737	The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. *British Journal of Pharmacology*, **2015**, 172, 5744-869	8.6	475
736	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. *Journal of Medicinal Chemistry*, **1992**, 35, 407-22	8.3	439
735	Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. *Journal of Experimental Medicine*, **2003**, 198, 783-96	16.6	395
734	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. *British Journal of Pharmacology*, **2019**, 176 Suppl 1, S21-S141	8.6	391
733	Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. *Trends in Pharmacological Sciences*, **2003**, 24, 52-5	13.2	351
732	Recent developments in adenosine receptor ligands and their potential as novel drugs. *Biochimica Et Biophysica Acta - Biomembranes*, **2011**, 1808, 1290-308	3.8	315
731	Purine and pyrimidine (P2) receptors as drug targets. *Journal of Medicinal Chemistry*, **2002**, 45, 4057-93	8.3	283
730	Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature*, **2014**, 509, 115-8	50.4	272
729	Adenosine A3 receptors: novel ligands and paradoxical effects. *Trends in Pharmacological Sciences*, **1998**, 19, 184-91	13.2	269
728	Towards a revised nomenclature for P1 and P2 receptors. *Trends in Pharmacological Sciences*, **1997**, 18, 79-82	13.2	265
727	Two disparate ligand-binding sites in the human P2Y1 receptor. *Nature*, **2015**, 520, 317-21	50.4	239
726	Adenosine receptor ligands: differences with acute versus chronic treatment. *Trends in Pharmacological Sciences*, **1996**, 17, 108-13	13.2	226

725	Agonist-bound structure of the human P2Y12 receptor. *Nature*, **2014**, 509, 119-22	50.4	222
724	Adenosine A3 receptor stimulation and cerebral ischemia. *European Journal of Pharmacology*, **1994**, 263, 59-67	5.3	220
723	Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. *Journal of Medicinal Chemistry*, **1994**, 37, 636-46	8.3	216
722	The Concise Guide to PHARMACOLOGY 2015/16: Overview. *British Journal of Pharmacology*, **2015**, 172, 5729-43	8.6	207
721	Structure-based discovery of A2A adenosine receptor ligands. *Journal of Medicinal Chemistry*, **2010**, 53, 3748-55	8.3	195
720	A physiological role of the adenosine A3 receptor: sustained cardioprotection. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 6995-9	11.5	186
719	2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1994**, 37, 3614-21	8.3	181
718	Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. *Journal of Medicinal Chemistry*, **2000**, 43, 1165-72	8.3	175
717	Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 706-21	8.3	171
716	Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate. *British Journal of Pharmacology*, **1998**, 124, 1-3	8.6	169
715	Pharmacological and therapeutic effects of A3 adenosine receptor agonists. *Drug Discovery Today*, **2012**, 17, 359-66	8.8	165
714	Molecular Architecture of G Protein-Coupled Receptors. *Drug Development Research*, **1996**, 37, 1-38	5.1	164
713	Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. *Journal of Biological Chemistry*, **1995**, 270, 13987-97	5.4	163
712	Medicinal chemistry of adenosine, P2Y and P2X receptors. *Neuropharmacology*, **2016**, 104, 31-49	5.5	158
711	Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. *Biochemical and Biophysical Research Communications*, **1996**, 219, 904-10	3.4	153
710	8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. *FEBS Letters*, **1993**, 323, 141-4	3.8	142
709	Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. *Journal of Neuroscience*, **1997**, 17, 607-14	6.6	141
708	Progress in the pursuit of therapeutic adenosine receptor antagonists. *Medicinal Research Reviews*, **2006**, 26, 131-59	14.4	139

707	Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary. *Journal of Medicinal Chemistry*, **2002**, 45, 4471-84	8.3	139
706	Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. *Journal of Medicinal Chemistry*, **1998**, 41, 1456-66	8.3	138
705	Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. *Journal of Medicinal Chemistry*, **1993**, 36, 1333-42	8.3	138
704	Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. *Bioconjugate Chemistry*, **2008**, 19, 1660-72	6.3	137
703	Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. *Journal of Medicinal Chemistry*, **1996**, 39, 4142-8	8.3	136
702	Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. *Neuropharmacology*, **1997**, 36, 1157-65	5.5	135
701	Adenosine A1 and A2 receptors: structure--function relationships. *Medicinal Research Reviews*, **1992** , 12, 423-71	14.4	131
700	Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain. *Cellular and Molecular Neurobiology*, **1993**, 13, 247-61	4.6	129
699	Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. *Journal of Medicinal Chemistry*, **2004**, 47, 5393-404	8.3	128
698	Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. *Biochemical Pharmacology*, **2004**, 67, 1763-70	6	127
697	Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. *Neuron*, **2015**, 87, 549-62	13.9	125
696	New paradigms in GPCR drug discovery. *Biochemical Pharmacology*, **2015**, 98, 541-55	6	124
695	Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. *Journal of Medicinal Chemistry*, **1998**, 41, 183-90	8.3	124
694	Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. *European Journal of Pharmacology*, **1995**, 287, 295-302	5.3	123
693	A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. *FEBS Letters* , **1993**, 336, 57-60	3.8	123
692	N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors. *Biochemical Pharmacology*, **2003**, 65, 1675-84	6	122
691	MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 316, 556-63	4.7	120
690	Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. *British Journal of Pharmacology*, **1994**, 113, 614-20	8.6	120

689	Allosteric Coupling of Drug Binding and Intracellular Signaling in the A Adenosine Receptor. *Cell*, **2018**, 172, 68-80.e12	56.2	119
688	Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. *Journal of Medicinal Chemistry*, **2003**, 46, 4847-59	8.3	119
687	The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. *Journal of Biological Chemistry*, **1999**, 274, 14639-47	5.4	119
686	P2Y nucleotide receptors: promise of therapeutic applications. *Drug Discovery Today*, **2010**, 15, 570-8	8.8	116
685	Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. *Blood*, **2005**, 105, 4707-14	2.2	116
684	Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. *Journal of Biological Chemistry*, **2002**, 277, 19056-63	5.4	116
683	2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. *Journal of Medicinal Chemistry*, **2003**, 46, 4974-87	8.3	115
682	Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. *Journal of Medicinal Chemistry*, **2000**, 43, 2196-203	8.3	114
681	Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1998**, 41, 3186-201	8.3	114
680	A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. *Molecular Pharmacology*, **1997**, 52, 499-507	4.3	113
679	Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. *Journal of Medicinal Chemistry*, **2000**, 43, 829-42	8.3	113
678	Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. *Biochemistry*, **1999**, 38, 3498-507	3.2	113
677	A-adenosine receptors: design of selective ligands and therapeutic prospects. *Drugs of the Future*, **1995**, 20, 689-699	2.3	111
676	Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. *Journal of Medicinal Chemistry*, **1993**, 36, 3937-46	8.3	107
675	Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 613-23	3.4	106
674	Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors. *Journal of Clinical Investigation*, **1996**, 98, 1773-9	15.9	104
673	Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1996**, 39, 2293-301	8.3	99
672	Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. *Journal of Medicinal Chemistry*, **1998**, 41, 2835-45	8.3	98

671	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. *Brain*, **2015**, 138, 28-35	11.2	97
670	Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 2980-9	8.3	97
669	Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. *Biochemical and Biophysical Research Communications*, **1997**, 232, 317-22	3.4	94
668	Interactions of flavonoids and other phytochemicals with adenosine receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 781-8	8.3	94
667	Structure Activity Relationships for Derivatives of Adenosine-5'-Triphosphate as Agonists at P(2) Purinoceptors: Heterogeneity Within P(2X) and P(2Y) Subtypes. *Drug Development Research*, **1994**, 31, 206-219	5.1	94
666	Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. *Brain, Behavior, and Immunity*, **2015**, 44, 91-9	16.6	93
665	Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3348-53	11.5	93
664	Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. *Frontiers in Cellular Neuroscience*, **2019**, 13, 124	6.1	92
663	Dihydropyridines as inhibitors of capacitative calcium entry in leukemic HL-60 cells. *Biochemical Pharmacology*, **2003**, 65, 329-38	6	89
662	Adenosine-induced cell death: evidence for receptor-mediated signalling. *Apoptosis: an International Journal on Programmed Cell Death*, **1999**, 4, 197-211	5.4	88
661	[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 4089-93	11.5	87
660	Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. *European Journal of Pharmacology*, **1994**, 256, 161-7	5.3	86
659	Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. *Journal of Medicinal Chemistry*, **2009**, 52, 3284-92	8.3	85
658	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. *Journal of Medicinal Chemistry*, **2005**, 48, 1745-58	8.3	85
657	Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. *Experimental Cell Research*, **1998**, 243, 383-97	4.2	85
656	Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. *Journal of Medicinal Chemistry*, **1995**, 38, 1174-88	8.3	85
655	Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. *Experimental Eye Research*, **2010**, 91, 425-32	3.7	84
654	Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. *Circulation Research*, **2006**, 98, 970-6	15.7	84

653	Xanthines as adenosine receptor antagonists. *Handbook of Experimental Pharmacology*, **2011**, 151-99	3.2	83
652	Development of selective agonists and antagonists of P2Y receptors. *Purinergic Signalling*, **2009**, 5, 75-89	3.8	83
651	Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 1038-43	4.7	83
650	Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. *Molecular Pharmacology*, **2002**, 62, 1249-57	4.3	83
649	Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. *Journal of Medicinal Chemistry*, **1985**, 28, 1334-40	8.3	83
648	Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. *FEBS Letters*, **1986**, 209, 122-8	3.8	83
647	A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. *Medicinal Research Reviews*, **2018**, 38, 1031-1072	14.4	82
646	Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. *Biochemical Pharmacology*, **2005**, 70, 266-74	6	81
645	[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. *Biochemical Pharmacology*, **2001**, 61, 657-63	6	81
644	Locomotor activity in mice during chronic treatment with caffeine and withdrawal. *Pharmacology Biochemistry and Behavior*, **1993**, 44, 199-216	3.9	81
643	Controlling murine and rat chronic pain through A3 adenosine receptor activation. *FASEB Journal*, **2012**, 26, 1855-65	0.9	80
642	Emerging adenosine receptor agonists. *Expert Opinion on Emerging Drugs*, **2007**, 12, 479-92	3.7	80
641	Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. *Journal of Medicinal Chemistry*, **2002**, 45, 208-18	8.3	80
640	Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 6572-6	11.5	80
639	The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. *Biochemical and Biophysical Research Communications*, **1997**, 241, 297-304	3.4	79
638	Correction: Ford et al., Engagement of the GABA to KCC2 Signaling Pathway Contributes to the Analgesic Effects of A3AR Agonists in Neuropathic Pain. *Journal of Neuroscience*, **2015**, 35, 8971-8971	6.6	78
637	Introduction to adenosine receptors as therapeutic targets. *Handbook of Experimental Pharmacology*, **2009**, 1-24	3.2	78
636	Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 7693-8	11.5	78

635	Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. *Cellular and Molecular Neurobiology*, **2003**, 23, 431-47	4.6	78
634	Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling. *Structure*, **2018**, 26, 259-269.e5	5.2	77
633	Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1997**, 40, 2596-608	8.3	77
632	Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. *Biochemical Pharmacology*, **2004**, 68, 1995-2002	6	77
631	Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. *Journal of Medicinal Chemistry*, **2001**, 44, 340-9	8.3	77
630	6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1996**, 39, 4667-75	8.3	77
629	A2B adenosine receptor blockade inhibits growth of prostate cancer cells. *Purinergic Signalling*, **2013**, 9, 271-80	3.8	76
628	N6-substituted D-4'-thioadenosine-5'-methyluronamides: potent and selective agonists at the human A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2003**, 46, 3775-7	8.3	76
627	Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. *Journal of Medicinal Chemistry*, **2001**, 44, 4125-36	8.3	76
626	Allosteric Modulation of A3 Adenosine Receptors by a Series of 3-(2-Pyridinyl)isoquinoline Derivatives. *Molecular Pharmacology*, **2001**, 60, 1057-1063	4.3	76
625	New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. *Molecular Pharmacology*, **2012**, 82, 361-71	4.3	75
624	Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. *Journal of Medicinal Chemistry*, **2007**, 50, 3159-62	8.3	75
623	2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. *British Journal of Pharmacology*, **2002**, 135, 2004-10	8.6	75
622	Heteromultimeric P2X(1/2) receptors show a novel sensitivity to extracellular pH. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 300, 673-80	4.7	75
621	Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. *Molecular Pharmacology*, **2015**, 88, 220-30	4.3	74
620	Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. *Molecular and Cellular Biochemistry*, **2001**, 217, 143-52	4.2	74
619	Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2002**, 45, 3440-50	8.3	74
618	A3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. *Pain*, **2014**, 155, 2560-2567	8	73

617	Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. *Molecular Pharmacology*, **2003**, 63, 1021-31	4.3	73
616	Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator. *Journal of Biological Chemistry*, **2002**, 277, 46622-31	5.4	73
615	Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. *Endocrinology*, **2000**, 141, 4156-63	4.8	73
614	Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders. *Annals of the New York Academy of Sciences*, **1997**, 825, 11-22	6.5	72
613	Update of P2Y receptor pharmacology: IUPHAR Review 27. *British Journal of Pharmacology*, **2020**, 177, 2413-2433	8.6	72
612	G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. *Purinergic Signalling*, **2012**, 8, 419-36	3.8	71
611	Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. *Ophthalmology*, **2010**, 117, 1287-93	7.3	71
610	A region in the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+. *Journal of Biological Chemistry*, **2005**, 280, 5113-20	5.4	71
609	Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. *Journal of Medicinal Chemistry*, **2002**, 45, 5694-709	8.3	71
608	The effects of adenosine A3 receptor stimulation on seizures in mice. *European Journal of Pharmacology*, **1995**, 275, 23-9	5.3	71
607	Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. *Naunyn-Schmiedebergis Archives of Pharmacology*, **2000**, 361, 225-34	3.4	70
606	Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. *Journal of Medicinal Chemistry*, **2012**, 55, 4847-60	8.3	69
605	Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. *Neurochemistry International*, **1998**, 32, 493-504	4.4	69
604	Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 6319-32	3.4	69
603	Human P2Y(6) receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. *Journal of Medicinal Chemistry*, **2005**, 48, 8108-11	8.3	69
602	Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. *Trends in Pharmacological Sciences*, **2005**, 26, 44-51	13.2	68
601	Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. *British Journal of Pharmacology*, **2003**, 138, 1451-8	8.6	68
600	Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist. *Journal of Medicinal Chemistry*, **2002**, 45, 3579-82	8.3	68

599	A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. *Molecular Pharmacology*, **2013**, 84, 41-9	4.3	67
598	Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. *Experimental Cell Research*, **2000**, 257, 111-26	4.2	67
597	2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. *Journal of Medicinal Chemistry*, **2006**, 49, 7373-83	8.3	66
596	Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. *Journal of Medicinal Chemistry*, **2006**, 49, 5532-43	8.3	66
595	Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. *American Journal of Physiology - Heart and Circulatory Physiology*, **2002**, 282, H2183-9	5.2	66
594	Species differences in ligand affinity at central A3-adenosine receptors. *Drug Development Research* , **1994**, 33, 51-59	5.1	66
593	8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. *Biochemistry*, **1997**, 36, 6455-61	3.2	65
592	Conformational changes involved in G-protein-coupled-receptor activation. *Trends in Pharmacological Sciences*, **2008**, 29, 616-25	13.2	65
591	Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. *Journal of Medicinal Chemistry*, **2002**, 45, 2131-8	8.3	65
590	Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. *Journal of Medicinal Chemistry*, **2001**, 44, 3092-108	8.3	65
589	Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists. *Journal of Medicinal Chemistry*, **1998**, 41, 3174-85	8.3	65
588	Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1995**, 38, 1720-35	8.3	65
587	Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. *Biochemical Pharmacology*, **2000**, 60, 661-8	6	64
586	Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. *FASEB Journal*, **2000**, 14, 1423-1431	0.9	64
585	Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 1249-61	5.8	64
584	5'-Phosphate and 5'-phosphonate ester derivatives of (N)-methanocarba adenosine with in vivo cardioprotective activity. *Journal of Medicinal Chemistry*, **2013**, 56, 902-14	8.3	63
583	Structure-activity relationship of (N)-Methanocarba phosphonate analogues of 5'-AMP as cardioprotective agents acting through a cardiac P2X receptor. *Journal of Medicinal Chemistry*, **2010** , 53, 2562-76	8.3	63
582	Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. *Molecular Pharmacology*, **2009**, 76, 1341-8	4.3	63

581	The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. *Current Eye Research*, **2005**, 30, 747-54	2.9	63
580	Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2006**, 49, 273-81	8.3	63
579	Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. *Journal of Medicinal Chemistry*, **1997**, 40, 2588-95	8.3	62
578	A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. *Molecular Pharmacology*, **2002**, 62, 1373-84	4.3	62
577	"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2005**, 48, 4910-8	8.3	60
576	1,3-dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors. *Drug Development Research*, **1999**, 47, 45-53	5.1	60
575	Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory. *European Journal of Pharmacology*, **1993**, 249, 271-80	5.3	60
574	Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. *FASEB Journal*, **1998**, 12, 1785-92	0.9	59
573	Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. *European Journal of Pharmacology*, **1993**, 249, 265-70	5.3	59
572	Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1994**, 37, 3373-82	8.3	59
571	Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding. *Biochemical Pharmacology*, **1992**, 43, 889-94	6	59
570	UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation. *Biochemical Pharmacology*, **2010**, 79, 873-9	6	58
569	Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. *FEBS Letters*, **1998**, 429, 139-42	3.8	58
568	Keynote review: allosterism in membrane receptors. *Drug Discovery Today*, **2006**, 11, 191-202	8.8	58
567	Allosteric modulation of the adenosine family of receptors. *Mini-Reviews in Medicinal Chemistry*, **2005**, 5, 545-53	3.2	58
566	Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). *Journal of Biological Chemistry*, **1998**, 273, 5727-34	5.4	58
565	CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. *Journal of Cellular Physiology*, **2011**, 226, 2438-47	7	57
564	Activity of Novel Adenine Nucleotide Derivatives as Agonists and Antagonists at Recombinant Rat P2X Receptors. *Drug Development Research*, **2000**, 49, 253-259	5.1	57

563	Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. *Current Pharmaceutical Design*, **2009**, 15, 3994-4002	3.3	56
562	Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. *Journal of Molecular and Cellular Cardiology*, **2005**, 39, 223-30	5.8	56
561	Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors. *Journal of Hypertension*, **2001**, 19, 1681-9	1.9	56
560	A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. *Journal of Medicinal Chemistry*, **1998**, 41, 2201-6	8.3	56
559	Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. *Journal of Medicinal Chemistry*, **1999**, 42, 1625-38	8.3	56
558	Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. *European Journal of Pharmacology*, **1996**, 308, 311-4	5.3	56
557	Non-xanthine heterocycles: activity as antagonists of A1- and A2-adenosine receptors. *Biochemical Pharmacology*, **1988**, 37, 655-64	6	56
556	Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. *Journal of Medicinal Chemistry*, **1985**, 28, 1341-6	8.3	56
555	Interactions of flavones and other phytochemicals with adenosine receptors. *Advances in Experimental Medicine and Biology*, **2002**, 505, 163-71	3.6	56
554	Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor. *Journal of Chemical Information and Modeling*, **2015**, 55, 550-63	6.1	55
553	Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. *Journal of Medicinal Chemistry*, **2012**, 55, 4297-308	8.3	55
552	The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. *Biochemical Pharmacology*, **2008**, 76, 482-94	6	55
551	Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. *Journal of Medicinal Chemistry*, **2007**, 50, 2030-9	8.3	55
550	Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. *Molecular Pharmacology*, **2002**, 62, 81-9	4.3	55
549	Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. *Journal of Medicinal Chemistry*, **2002**, 45, 2090-100	8.3	55
548	Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. *Journal of Medicinal Chemistry*, **1998**, 41, 46-52	8.3	55
547	Novel therapeutics acting via purine receptors. *Biochemical Pharmacology*, **1991**, 41, 1399-410	6	55
546	CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. *Biochemical Pharmacology*, **2005**, 71, 115-25	6	54

545	Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 3055-65	8.3	54
544	Chronic adenosine A1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizures in mice. *European Journal of Pharmacology*, **1994**, 253, 95-9	5.3	54
543	18F-labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. *Biochemistry*, **1989**, 28, 4801-6	3.2	54
542	Molecular probes for extracellular adenosine receptors. *Biochemical Pharmacology*, **1987**, 36, 1697-707	6	54
541	Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. *Blood*, **2019**, 134, 395-406	2.2	53
540	Renal intercalated cells sense and mediate inflammation via the P2Y14 receptor. *PLoS ONE*, **2015**, 10, e0121419	3.7	53
539	Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain. *Journal of Neuroscience*, **2015**, 35, 6057-67	6.6	53
538	Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 2021-34	3.4	53
537	p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. *Biochemical Pharmacology*, **2002**, 63, 871-80	6	53
536	Recent developments in selective agonists and antagonists acting at purine and pyrimidine receptors. *Drug Development Research*, **1996**, 39, 289-300	5.1	53
535	Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells. *Life Sciences*, **1986**, 38, 797-807	6.8	53
534	Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. *British Journal of Pharmacology*, **2021**, 178, 489-514	8.6	53
533	UDP is a competitive antagonist at the human P2Y14 receptor. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325, 588-94	4.7	52
532	Role of adenosine A3 receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. *Biochemical Pharmacology*, **2007**, 74, 768-79	6	52
531	2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. *Biochemical Pharmacology*, **2004**, 68, 1985-93	6	52
530	Chemotherapy-induced pain is promoted by enhanced spinal adenosine kinase levels through astrocyte-dependent mechanisms. *Pain*, **2018**, 159, 1025-1034	8	51
529	Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. *Biochemical Pharmacology*, **2011**, 82, 658-68	6	51
528	Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct. *Biochemical Pharmacology*, **2006**, 72, 949-55	6	51

527	Comparative studies on the affinities of ATP derivatives for P2x-purinoceptors in rat urinary bladder. *British Journal of Pharmacology*, **1994**, 112, 1151-9	8.6	51
526	Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics. *British Journal of Pharmacology*, **2016**, 173, 1253-67	8.6	51
525	Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress. *Biochemical Pharmacology*, **2005**, 69, 1215-23	6	50
524	Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. *European Journal of Pharmacology*, **1999**, 367, 157-63	5.3	50
523	Characterization of the locomotor depression produced by an A2-selective adenosine agonist. *FEBS Letters*, **1990**, 261, 67-70	3.8	50
522	Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 293, H3685-91	5.2	49
521	A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. *Journal of Biological Chemistry*, **2000**, 275, 30272-9	5.4	49
520	A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. *Biochemistry*, **1995**, 34, 9079-87	3.2	49
519	A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. *Critical Care*, **2006**, 10, R65	10.8	47
518	Tumor necrosis factor alpha-induced apoptosis in astrocytes is prevented by the activation of P2Y6, but not P2Y4 nucleotide receptors. *Biochemical Pharmacology*, **2003**, 65, 923-31	6	47
517	A conformationally locked analogue of the anti-HIV agent stavudine. An important correlation between pseudorotation and maximum amplitude. *Journal of Medicinal Chemistry*, **2003**, 46, 3292-9	8.3	47
516	Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate ester modifications as selective agonists of the P2Y(4) receptor. *Journal of Medicinal Chemistry*, **2011**, 54, 4018-33	8.3	46
515	Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists. *PLoS ONE*, **2012**, 7, e49910	3.7	46
514	Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5'-monophosphate. *British Journal of Pharmacology*, **1996**, 118, 1959-64	8.6	46
513	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S27-S156	8.6	46
512	Rapid identification of functionally critical amino acids in a G protein-coupled receptor. *Nature Methods*, **2007**, 4, 169-74	21.6	45
511	Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. *Biochemical Pharmacology*, **2006**, 72, 1031-41	6	45
510	Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. *Current Topics in Medicinal Chemistry*, **2004**, 4, 805-19	3	45

509	Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 2995-3007	3.4	45
508	Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. *Biochemical Pharmacology*, **2003**, 65, 525-34	6	45
507	A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. *Nucleosides & Nucleotides*, **1998**, 17, 969-85		45
506	Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist. *European Journal of Pharmacology*, **1999**, 369, 313-7	5.3	45
505	Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 802-6	8.3	45
504	The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. *Neurochemistry International*, **2010**, 56, 35-41	4.4	44
503	Role of direct RhoA-phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. *FASEB Journal*, **2004**, 18, 406-8	0.9	44
502	Synthesis using ring closure metathesis and effect on nucleoside transport of a (N)-methanocarba S-(4-nitrobenzyl)thioinosine derivative. *Organic Letters*, **2001**, 3, 597-9	6.2	44
501	Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. *European Journal of Pharmacology*, **1996**, 316, 171-9	5.3	44
500	Molecular modeling studies of human A3 adenosine antagonists: structural homology and receptor docking. *Journal of Chemical Information and Computer Sciences*, **1998**, 38, 1239-48		43
499	Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. *Biochemical Pharmacology*, **2006** , 71, 540-9	6	43
498	A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. *Journal of Biological Chemistry*, **2006**, 281, 21558-21565	5.4	43
497	Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H2792-801	5.2	43
496	P2Y6 nucleotide receptor activates PKC to protect 1321N1 astrocytoma cells against tumor necrosis factor-induced apoptosis. *Cellular and Molecular Neurobiology*, **2003**, 23, 401-18	4.6	43
495	Hypothermia in mouse is caused by adenosine A and A receptor agonists and AMP via three distinct mechanisms. *Neuropharmacology*, **2017**, 114, 101-113	5.5	42
494	Molecular determinants of A2AR-D2R allosterism: role of the intracellular loop 3 of the D2R. *Journal of Neurochemistry*, **2012**, 123, 373-84	6	42
493	Small molecule positive allosteric modulation of TRPV1 activation by vanilloids and acidic pH. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 152-60	4.7	42
492	Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A3 adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide. *Bioconjugate Chemistry*, **2010**, 21, 372-84	6.3	42

491	Dexamethasone enhances ATP-induced inflammatory responses in endothelial cells. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 335, 693-702	4.7	42
490	Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. *Journal of Biological Chemistry*, **2007**, 282, 26284-93	5.4	42
489	Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. *Journal of Medicinal Chemistry*, **2007**, 50, 1810-27	8.3	42
488	2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 347-56	3.4	42
487	Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1333-7	2.9	42
486	Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. *Journal of Medicinal Chemistry*, **1993**, 36, 2639-44	8.3	42
485	Purinergic Signaling in Mast Cell Degranulation and Asthma. *Frontiers in Pharmacology*, **2017**, 8, 947	5.6	41
484	In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. *Journal of Medicinal Chemistry*, **2014**, 57, 9901-14	8.3	41
483	Potential for developing purinergic drugs for gastrointestinal diseases. *Inflammatory Bowel Diseases*, **2014**, 20, 1259-87	4.5	41
482	Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). *Bioconjugate Chemistry*, **2009**, 20, 1816-35	6.3	41
481	Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay. *Biochemical Pharmacology*, **2010**, 80, 506-11	6	41
480	Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. *Annals of the New York Academy of Sciences*, **1997**, 825, 23-9	6.5	41
479	Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. *Bioconjugate Chemistry*, **2008**, 19, 406-11	6.3	41
478	Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2006**, 49, 3354-61	8.3	41
477	Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2005**, 280, 34849-58	5.4	41
476	Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. *Journal of Medicinal Chemistry*, **1992**, 35, 4143-9	8.3	41
475	Allosteric modulation and functional selectivity of G protein-coupled receptors. *Drug Discovery Today: Technologies*, **2013**, 10, e237-43	7.1	40
474	Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. *Journal of Medicinal Chemistry*, **2012**, 55, 8075-90	8.3	40

473	Pharmacochemistry of the platelet purinergic receptors. *Purinergic Signalling*, **2011**, 7, 305-24	3.8	40
472	Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. *Journal of Medicinal Chemistry*, **2009**, 52, 7580-92	8.3	40
471	The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor. *Trends in Pharmacological Sciences*, **2005**, 26, 8-9	13.2	40
470	Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. *European Journal of Pharmacology*, **1994**, 268, 95-104		40
469	Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. *Handbook of Experimental Pharmacology*, **2009**, 123-59	3.2	40
468	Design of (N)-methanocarba adenosine 5′-uronamides as species-independent A3 receptor-selective agonists. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2813-9	2.9	39
467	Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. *Journal of Medicinal Chemistry*, **2006**, 49, 2689-702	8.3	39
466	Roles of BCL-2 and caspase 3 in the adenosine A3 receptor-induced apoptosis. *Journal of Molecular Neuroscience*, **2001**, 17, 285-92	3.3	39
465	Conjugates of catecholamines. 1. N-alkyl-functionalized carboxylic acid congeners and amides related to isoproterenol. *Journal of Medicinal Chemistry*, **1983**, 26, 492-9	8.3	39
464	Adenine nucleotide control of coronary blood flow during exercise. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H1981-9	5.2	38
463	Adenosine A3 receptors and viability of astrocytes **1998**, 45, 379-386		38
462	Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2′-amino-2′-deoxy-2-thiouridine 5′-triphosphate. *Journal of Medicinal Chemistry*, **2007**, 50, 1166-76	8.3	38
461	Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. *Journal of Molecular Graphics and Modelling*, **2006**, 25, 562-77	2.8	38
460	A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists. *Chemistry and Biology*, **2005**, 12, 237-47		38
459	Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis. *Biochemical and Biophysical Research Communications*, **2001**, 284, 596-601	3.4	38
458	Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. *Journal of Medicinal Chemistry*, **2013**, 56, 5949-63	8.3	37
457	Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons **1997**, 40, 267-273		37
456	Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. *Organic and Biomolecular Chemistry*, **2005**, 3, 2016-25	3.9	37

455	[32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. *British Journal of Pharmacology*, **2006**, 147, 459-67	8.6	37
454	Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. *European Journal of Pharmacology*, **1996**, 302, 43-8	5.3	37
453	Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain. *Purinergic Signalling*, **2015**, 11, 371-87	3.8	36
452	Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A2A adenosine receptor. *Journal of Medicinal Chemistry*, **2012**, 55, 538-52	8.3	36
451	Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. *Journal of Medicinal Chemistry*, **2010**, 53, 471-80	8.3	36
450	Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 596-601	2.9	36
449	2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. *Biochemical Pharmacology*, **2004**, 68, 231-7	6	36
448	Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling. *Chemical Communications*, **2003**, 2949-56	5.8	36
447	Synthesis of novel apio carbocyclic nucleoside analogues as selective a(3) adenosine receptor agonists. *Journal of Organic Chemistry*, **2005**, 70, 5006-13	4.2	36
446	Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies. *Journal of Medicinal Chemistry*, **2001**, 44, 2735-42	8.3	36
445	Agonist derived molecular probes for A2 adenosine receptors. *Journal of Molecular Recognition*, **1989**, 2, 170-8	2.6	36
444	Ocular Purine Receptors as Drug Targets in the Eye. *Journal of Ocular Pharmacology and Therapeutics*, **2016**, 32, 534-547	2.6	35
443	Molecular modeling of a PAMAM-CGS21680 dendrimer bound to an A2A adenosine receptor homodimer. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4312-5	2.9	35
442	Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors. *Biochemistry*, **1995**, 34, 9088-94	3.2	35
441	Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information. *Journal of Computer-Aided Molecular Design*, **2015**, 29, 737-56	4.2	34
440	UDP-glucose promotes neutrophil recruitment in the lung. *Purinergic Signalling*, **2016**, 12, 627-635	3.8	34
439	The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. *Purinergic Signalling*, **2013**, 9, 31-40	3.8	34
438	Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. *Biochemical Pharmacology*, **2011**, 82, 418-25	6	34

437	Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 8546-56	3.4	34
436	Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. *Journal of Medicinal Chemistry*, **1989**, 32, 1043-51	8.3	34
435	A [3H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A2 adenosine receptors of human platelets. *FEBS Letters*, **1986**, 199, 269-74	3.8	34
434	Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 3677-3695	8.3	33
433	Identification of a new dysfunctional platelet P2Y12 receptor variant associated with bleeding diathesis. *Blood*, **2015**, 125, 1006-13	2.2	33
432	A Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists. *Drug Development Research*, **1998**, 45, 113-124	5.1	33
431	Role of P2X purinergic receptors in the rescue of ischemic heart failure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H1191-H1197	5.2	33
430	Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety. *Biochemical Pharmacology*, **2004**, 67, 893-901	6	33
429	Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 77-85	3.4	33
428	Sulfur-containing 1,3-dialkylxanthine derivatives as selective antagonists at A1-adenosine receptors. *Journal of Medicinal Chemistry*, **1989**, 32, 1873-9	8.3	33
427	On the selectivity of the G□ inhibitor UBO-QIC: A comparison with the G□inhibitor pertussis toxin. *Biochemical Pharmacology*, **2016**, 107, 59-66	6	33
426	Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand. *Bioconjugate Chemistry*, **2014**, 25, 1847-54	6.3	32
425	Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. *Journal of Medicinal Chemistry*, **2009**, 52, 2098-108	8.3	32
424	P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. *Journal of Medicinal Chemistry*, **2007**, 50, 3229-41	8.3	32
423	Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. *BMC Pharmacology*, **2008**, 8, 20		32
422	Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling. *Journal of Receptors and Signal Transduction*, **1992**, 12, 149-69		32
421	Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor. *Molecular Pharmacology*, **2016**, 90, 12-22	4.3	31
420	Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists. *PLoS ONE*, **2014**, 9, e116203	3.7	31

419	Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands. *Journal of Medicinal Chemistry*, **2012**, 55, 342-56	8.3	31
418	Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. *Experimental Eye Research*, **2010**, 90, 146-54	3.7	31
417	Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways. *Pharmacological Research*, **2008**, 57, 303-11	10.2	31
416	Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **2008**, 51, 6609-13	8.3	31
415	Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection. *Journal of Medicinal Chemistry*, **2005**, 48, 8103-7	8.3	31
414	(N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 861-8	15.4	31
413	Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor. *Journal of Biological Chemistry*, **2005**, 280, 24870-9	5.4	31
412	Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors. *British Journal of Pharmacology*, **1995**, 116, 2611-6	8.6	31
411	Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives. *Journal of Medicinal Chemistry*, **1994**, 37, 4020-30	8.3	31
410	Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. *Journal of Medicinal Chemistry*, **2016**, 59, 6149-68	8.3	30
409	Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor. *Biochemical Pharmacology*, **2014**, 90, 297-306	6	30
408	Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes. *ACS Chemical Biology*, **2014**, 9, 2833-42	4.9	30
407	Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility. *Journal of Medicinal Chemistry*, **2011**, 54, 877-89	8.3	30
406	Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. *Journal of Computer-Aided Molecular Design*, **2011**, 25, 329-38	4.2	30
405	PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. *Bioconjugate Chemistry*, **2009**, 20, 1888-98	6.3	30
404	Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. *Pharmacological Research*, **2008**, 58, 232-9	10.2	30
403	Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 5619-30	3.4	30
402	Random mutagenesis of the M3 muscarinic acetylcholine receptor expressed in yeast: identification of second-site mutations that restore function to a coupling-deficient mutant M3 receptor. *Journal of Biological Chemistry*, **2005**, 280, 5664-75	5.4	30

401	Interaction of dihydropyridine calcium channel agonists and antagonists with adenosine receptors. *Basic and Clinical Pharmacology and Toxicology*, **1987**, 61, 121-5		30
400	8-Substituted xanthines as antagonists at A1- and A2-adenosine receptors. *Biochemical Pharmacology*, **1988**, 37, 3653-61	6	30
399	Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5298-311	3.4	29
398	Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic beta cells. *Biochemical Pharmacology*, **2010**, 79, 1317-26	6	29
397	Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 2524-36	3.4	29
396	Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists. *Drug Development Research*, **1998**, 45, 52-66	5.1	29
395	Adenosine A(2A) receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC. *European Journal of Pharmacology*, **2008**, 590, 36-42	5.3	29
394	Structure-activity relationships of 1,4-dihydropyridines that act as enhancers of the vanilloid receptor 1 (TRPV1). *Bioorganic and Medicinal Chemistry*, **2008**, 16, 9349-58	3.4	29
393	Defining the nucleotide binding sites of P2Y receptors using rhodopsin-based homology modeling. *Journal of Computer-Aided Molecular Design*, **2006**, 20, 417-26	4.2	29
392	Adenosine: a prototherapeutic concept in neurodegeneration. *Annals of the New York Academy of Sciences*, **1995**, 765, 163-78; discussion 196-7	6.5	29
391	Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. *European Journal of Pharmacology*, **1996**, 310, 269-72	5.3	29
390	"Mediator methodology" for the synthesis of peptides in a two-polymeric system. *Journal of the American Chemical Society*, **1985**, 107, 4249-4252	16.4	29
389	South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase. *Journal of Medicinal Chemistry*, **2016**, 59, 6860-77	8.3	28
388	Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry. *Biochemical Pharmacology*, **2012**, 83, 1552-61	6	28
387	Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A adenosine receptor binding site. *Scientific Reports*, **2017**, 7, 6398	4.9	28
386	Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. *Journal of Medicinal Chemistry*, **2010**, 53, 4488-501	8.3	28
385	Allosteric modulation of purine and pyrimidine receptors. *Advances in Pharmacology*, **2011**, 61, 187-220	5.7	28
384	Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. *Combinatorial Chemistry and High Throughput Screening*, **2008**, 11, 410-9	1.3	28

383	P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H1077-84	5.2	28
382	Synthesis of a novel conformationally locked carbocyclic nucleoside ring system. *Organic Letters*, **2003**, 5, 1665-8	6.2	28
381	Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors. *Drug Development Research*, **1999**, 47, 178-188	5.1	28
380	P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo. *Purinergic Signalling*, **2013**, 9, 633-42	3.8	27
379	Fluorescent ligands for adenosine receptors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 26-36	2.9	27
378	Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. *Journal of Medicinal Chemistry*, **2013**, 56, 3749-67	8.3	27
377	Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor. *Proteins: Structure, Function and Bioinformatics*, **2011**, 79, 1878-97	4.2	27
376	Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([(125)I]MRS2500). *Pharmacological Research*, **2010**, 62, 344-51	10.2	27
375	Comparative molecular field analysis of selective A3 adenosine receptor agonists. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 1331-43	3.4	27
374	A SURVEY OF NONXANTHINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS. *Nucleosides & Nucleotides*, **1996**, 15, 693-717		27
373	A Adenosine Receptor and Cancer. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	26
372	Physiology and effects of nucleosides in mice lacking all four adenosine receptors. *PLoS Biology*, **2019**, 17, e3000161	9.7	26
371	Treatment of chronic neuropathic pain: purine receptor modulation. *Pain*, **2020**, 161, 1425-1441	8	26
370	Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism. *ACS Chemical Biology*, **2014**, 9, 2496-501	4.9	26
369	P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells. *Pharmacological Research*, **2010**, 62, 500-5	10.2	26
368	The A3 adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. *Annals of the New York Academy of Sciences*, **2001**, 939, 63-73	6.5	26
367	Nucleotide coronary vasodilation in guinea pig hearts. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 285, H1040-7	5.2	26
366	The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 31-4	2.9	26

365	Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells. *Journal of Membrane Biology*, **2000**, 178, 103-13	2.3	26
364	Acyclic analogues of deoxyadenosine 3',5'-bisphosphates as P2Y(1) receptor antagonists. *Journal of Medicinal Chemistry*, **2000**, 43, 746-55	8.3	26
363	Simultaneous determination of histamine and N tau-methylhistamine with high-performance liquid chromatography using electrochemical detection. *Analytical Biochemistry*, **1986**, 152, 127-35	3.1	26
362	The role of activated adenosine receptors in degranulation of human LAD2 mast cells. *Purinergic Signalling*, **2014**, 10, 465-75	3.8	25
361	Novel protective role of endogenous cardiac myocyte P2X4 receptors in heart failure. *Circulation: Heart Failure*, **2014**, 7, 510-8	7.6	25
360	Computational studies to predict or explain G protein coupled receptor polypharmacology. *Trends in Pharmacological Sciences*, **2014**, 35, 658-63	13.2	25
359	Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425. *Nuclear Medicine and Biology*, **2011**, 38, 897-906	2.1	25
358	Neoceptors: reengineering GPCRs to recognize tailored ligands. *Trends in Pharmacological Sciences*, **2007**, 28, 111-6	13.2	25
357	A new synthetic route to (North)-methanocarba nucleosides designed as A3 adenosine receptor agonists. *Journal of Organic Chemistry*, **2005**, 70, 439-47	4.2	25
356	Computational prediction of homodimerization of the A3 adenosine receptor. *Journal of Molecular Graphics and Modelling*, **2006**, 25, 549-61	2.8	25
355	Characterization of adenosine receptors in intact cultured heart cells. *Biochemical Pharmacology*, **1994**, 48, 727-35	6	25
354	Functionalized congener approach to muscarinic antagonists: analogues of pirenzepine. *Journal of Medicinal Chemistry*, **1991**, 34, 2133-45	8.3	25
353	On the G protein-coupling selectivity of the native A adenosine receptor. *Biochemical Pharmacology* , **2018**, 151, 201-213	6	25
352	Agonists and antagonists for P2 receptors. *Novartis Foundation Symposium*, **2006**, 276, 58-68; discussion 68-72, 107-12, 275-81		25
351	Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists. *ACS Chemical Biology*, **2016**, 11, 2763-2772	4.9	24
350	Extrinsic Tryptophans as NMR Probes of Allosteric Coupling in Membrane Proteins: Application to the A Adenosine Receptor. *Journal of the American Chemical Society*, **2018**, 140, 8228-8235	16.4	24
349	Portraying G protein-coupled receptors with fluorescent ligands. *ACS Chemical Biology*, **2014**, 9, 1918-28	4.9	24
348	Polypharmacology of N-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) Partial Agonist and PPAR Antagonist Activity Suggests Their Antidiabetic Potential. *Journal of Medicinal Chemistry*, **2017**, 60, 7459-7475	8.3	24

347	GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists. *Bioconjugate Chemistry*, **2011**, 22, 1115-27	6.3	24
346	Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography. *Nuclear Medicine and Biology*, **2009**, 36, 3-10	2.1	24
345	Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart. *Molecular Pharmacology*, **1997**, 52, 491-8	4.3	24
344	Evidence for the Recognition of Non-Nucleotide Antagonists Within the Transmembrane Domains of the Human P2Y(1) Receptor. *Drug Development Research*, **2002**, 57, 173-181	5.1	24
343	Growth, Texture, and Surface Morphology of SiC Layers. *Journal of the Electrochemical Society*, **1971**, 118, 1001	3.9	24
342	Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. *Pain*, **2019**, 160, 1103-1118	8	24
341	Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. *Journal of Computer-Aided Molecular Design*, **2009**, 23, 747-54	4.2	23
340	"Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. *Bioconjugate Chemistry*, **1995**, 6, 255-63	6.3	23
339	Purification and characterization of bovine cerebral cortex A1 adenosine receptor. *Archives of Biochemistry and Biophysics*, **1990**, 283, 440-6	4.1	23
338	A PROSTHETIC GROUP FOR THE RAPID INTRODUCTION OF FLUORINE INTO PEPTIDES AND FUNCTIONALIZED DRUGS. *Journal of Fluorine Chemistry*, **1988**, 39, 339-47	2.1	23
337	Characterization of Polyamidoamino (PAMAM) Dendrimers Using In-Line Reversed Phase LC Electrospray Ionization Mass Spectrometry. *Analytical Methods*, **2016**, 8, 263-269	3.2	22
336	Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects. *Journal of the American Chemical Society*, **2014**, 136, 12296-303	16.4	22
335	Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2740-5	2.9	22
334	2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 508-17	3.4	22
333	Ligand-specific changes in M3 muscarinic acetylcholine receptor structure detected by a disulfide scanning strategy. *Biochemistry*, **2008**, 47, 2776-88	3.2	22
332	Potent P2X Receptor Antagonists: Tyrosyl Derivatives Synthesized Using a Sequential Parallel Synthetic Approach. *Drug Development Research*, **2001**, 54, 75-87	5.1	22
331	Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists. *Journal of Medicinal Chemistry*, **1996**, 39, 398-406	8.3	22
330	A selective agonist affinity label for A3 adenosine receptors. *Biochemical and Biophysical Research Communications*, **1994**, 203, 570-6	3.4	22

329	2-[2-[4-[2-[2-[1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'--ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A-Adenosine Receptors. *Journal of Fluorescence*, **1992**, 2, 217-223	2.4	22
328	Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. *Bioconjugate Chemistry*, **2009**, 20, 1650-9	6.3	21
327	Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A adenosine receptor. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 340, 210-7	4.7	21
326	Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5690-4	2.9	21
325	Synthesis of ethyl (1S,2R,3S,4S,5S)-2,3-O-(isopropylidene)-4-hydroxy-bicyclo[3.1.0]hexane-carboxylate from L-ribose: a versatile chiral synthon for preparation of adenosine and P2 receptor ligands. *Nucleosides, Nucleotides and Nucleic Acids*, **2008**, 27, 279-91	1.4	21
324	Evidence for the possible involvement of the P2Y(6) receptor in Ca (2+) mobilization and insulin secretion in mouse pancreatic islets. *Purinergic Signalling*, **2008**, 4, 365-75	3.8	21
323	Design, synthesis, and biological activity of N6-substituted-4'-thioadenosines at the human A3 adenosine receptor. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 4718-30	3.4	21
322	Structure-Guided Modification of Heterocyclic Antagonists of the P2Y Receptor. *Journal of Medicinal Chemistry*, **2018**, 61, 4860-4882	8.3	21
321	Structural Probing and Molecular Modeling of the A Adenosine Receptor: A Focus on Agonist Binding. *Molecules*, **2017**, 22,	4.8	20
320	Distinct Signaling Patterns of Allosteric Antagonism at the P2Y Receptor. *Molecular Pharmacology*, **2017**, 92, 613-626	4.3	20
319	Virtual screening leads to the discovery of novel non-nucleotide P2Y receptor antagonists. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 5254-61	3.4	20
318	Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes. *Environmental Sciences Europe*, **2012**, 1, 815	5	20
317	Dopamine D(2) receptor-mediated modulation of adenosine A(2A) receptor agonist binding within the A(2A)R/D(2)R oligomer framework. *Neurochemistry International*, **2013**, 63, 42-6	4.4	20
316	Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. *Current Pharmaceutical Design*, **2002**, 8, 2401-13	3.3	20
315	Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists. *Journal of Pharmaceutical Sciences*, **1994**, 83, 46-53	3.9	20
314	Adenosine A1 receptor and ligand molecular modeling. *Drug Development Research*, **1993**, 28, 237-243	5.1	20
313	Xanthine functionalized congeners as potent ligands at A2-adenosine receptors. *Journal of Medicinal Chemistry*, **1987**, 30, 211-4	8.3	20
312	The role of adenosine receptors in the central action of caffeine **1994**, 7, 201-213		20

311	Adenosine A receptor antagonists: from caffeine to selective non-xanthines. *British Journal of Pharmacology*, **2020**,	8.6	19
310	Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists. *Journal of Medicinal Chemistry*, **2014**, 57, 1344-54	8.3	19
309	A adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. *Mediators of Inflammation*, **2014**, 2014, 708746	4.3	19
308	Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. *BMC Pharmacology*, **2011**, 11, 11		19
307	Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. *Bioconjugate Chemistry*, **2010**, 21, 1190-205	6.3	19
306	Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3002-5	2.9	19
305	Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 761-6	2.9	19
304	Coronary artery reperfusion: The ADP receptor P2Y(1) mediates early reactive hyperemia in vivo in pigs. *Purinergic Signalling*, **2004**, 1, 59-65	3.8	19
303	Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 817-20	2.9	19
302	Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. *Life Sciences*, **2004**, 74, 3173-80	6.8	19
301	Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 973-83	3.4	19
300	Characterization of "mini-nucleotides" as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study. *Journal of Medicinal Chemistry*, **1999**, 42, 2685-96	8.3	19
299	Probing the adenosine receptor with adenosine and xanthine biotin conjugates. *FEBS Letters*, **1985**, 184, 30-5	3.8	19
298	Liquid chromatographic assay for cerebrospinal fluid serotonin. *Life Sciences*, **1986**, 38, 687-94	6.8	19
297	Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4056-64	3.4	18
296	Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke. *Experimental Neurology*, **2020**, 329, 113308	5.7	18
295	Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 356, 474-82	4.7	18
294	Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy. *ACS Medicinal Chemistry Letters*, **2015**, 6, 804-8	4.3	18

293	Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor. *Biochemical Pharmacology*, **2010**, 79, 967-73	6	18
292	Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates. *Journal of Nanobiotechnology*, **2008**, 6, 12	9.4	18
291	Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures. *Molecular and Cellular Biochemistry*, **2003**, 252, 133-9	4.2	18
290	Amphiphilic pyridinium salts block TNF alpha/NF kappa B signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. *Biochemical Pharmacology*, **2005**, 70, 381-93	6	18
289	Purine derivatives as ligands for A3 adenosine receptors. *Current Topics in Medicinal Chemistry*, **2005**, 5, 1275-95	3	18
288	Additive effects of late preconditioning produced by monophosphoryl lipid A and the early preconditioning mediated by adenosine receptors and KATP channel. *Circulation*, **1999**, 99, 3300-7	16.7	18
287	Effect of adenosine on Na+ and Cl- currents in A6 monolayers. Receptor localization and messenger involvement. *Journal of Membrane Biology*, **1996**, 151, 237-45	2.3	18
286	Avian and human homologues of the P2Y1 receptor: Pharmacological, signaling, and molecular properties. *Drug Development Research*, **1996**, 39, 253-261	5.1	18
285	Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. *Naunyn-Schmiedebergis Archives of Pharmacology*, **1993**, 347, 521-6	3.4	18
284	Potent convulsant actions of the adenosine receptor antagonist, xanthine amine congener (XAC). *Life Sciences*, **1989**, 45, 719-28	6.8	18
283	Chronic Morphine-Induced Changes in Signaling at the A Adenosine Receptor Contribute to Morphine-Induced Hyperalgesia, Tolerance, and Withdrawal. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 374, 331-341	4.7	18
282	N-Substituted 5'-N-Methylcarbamoyl-4'-selenoadenosines as Potent and Selective A Adenosine Receptor Agonists with Unusual Sugar Puckering and Nucleobase Orientation. *Journal of Medicinal Chemistry*, **2017**, 60, 3422-3437	8.3	17
281	Purinergic drug targets for gastrointestinal disorders. *Current Opinion in Pharmacology*, **2017**, 37, 131-141	5.1	17
280	Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congeners. *PLoS ONE*, **2014**, 9, e97858	3.7	17
279	Anti-ischemic effects of multivalent dendrimeric A□adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart. *Pharmacological Research*, **2012**, 65, 338-46	10.2	17
278	GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs?. *Trends in Pharmacological Sciences*, **2010**, 31, 575-9	13.2	17
277	Involvement of UTP in protection of cardiomyocytes from hypoxic stress. *Canadian Journal of Physiology and Pharmacology*, **2009**, 87, 287-99	2.4	17
276	Stimulation of Xenopus P2Y1 receptor activates CFTR in A6 cells. *Pflugers Archiv European Journal of Physiology*, **2004**, 449, 66-75	4.6	17

275	Actions of a Series of PPADS Analogs at P2X and P2X Receptors. *Drug Development Research*, **2001**, 53, 281-291	5.1	17
274	Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. *Progress in Brain Research*, **1999**, 120, 119-32	2.9	17
273	Adenosine Receptors:Selective Agonists and Antagonists **1995**, 157-166		17
272	4-Alkyloxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptors. *Journal of Medicinal Chemistry*, **2014**, 57, 3874-83	8.3	16
271	Demystifying P2Y Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses. *Journal of Chemical Information and Modeling*, **2017**, 57, 3104-3123	6.1	16
270	Structure-Based Design, Synthesis by Click Chemistry and Activity of Highly Selective A Adenosine Receptor Agonists. *MedChemComm*, **2015**, 6, 555-563	5	16
269	Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions. *ACS Medicinal Chemistry Letters*, **2012**, 3, 596-601	4.3	16
268	Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3733-8	3.4	16
267	Three-dimensional quantitative structure-activity relationship of nucleosides acting at the A3 adenosine receptor: analysis of binding and relative efficacy. *Journal of Chemical Information and Modeling*, **2007**, 47, 1225-33	6.1	16
266	Synthesis and structure-activity relationship studies of tyrosine-based antagonists at the human P2X7 receptor. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 571-5	2.9	16
265	The Anti-Cancer Effect of A Adenosine Receptor Agonists: A Novel, Targeted Therapy. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2007**, 7, 298-303		16
264	2-Chloro-N(6)-cyclopentyladenosine, adenosine A(1) receptor agonist, antagonizes the adenosine A(3) receptor. *European Journal of Pharmacology*, **2002**, 443, 39-42	5.3	16
263	Synthesis and purine receptor affinity of 6-oxopurine nucleosides and nucleotides containing (N)-methanocarba-pseudoribose rings. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 2295-300	2.9	16
262	Trifunctional agents as a design strategy for tailoring ligand properties: irreversible inhibitors of A1 adenosine receptors. *Bioconjugate Chemistry*, **1991**, 2, 77-88	6.3	16
261	Autoradiographic localization of mouse brain adenosine receptors with an antagonist ([3H]xanthine amine congener) ligand probe. *Neuroscience Letters*, **1988**, 86, 121-6	3.3	16
260	Assessment of biased agonism at the A adenosine receptor using □arrestin and miniG□ recruitment assays. *Biochemical Pharmacology*, **2020**, 177, 113934	6	16
259	Lack of adipocyte purinergic P2Y receptor greatly improves whole body glucose homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 30763-30774	11.5	16
258	Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents. *Pain*, **2020**, 161, 177-184	8	16

257	Exploring the Role of N-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ?. *Journal of Medicinal Chemistry*, **2017**, 60, 4327-4341	8.3	15
256	Accelerating the Throughput of Affinity Mass Spectrometry-Based Ligand Screening toward a G Protein-Coupled Receptor. *Analytical Chemistry*, **2019**, 91, 8162-8169	7.8	15
255	Remote control of movement disorders using a photoactive adenosine A receptor antagonist. *Journal of Controlled Release*, **2018**, 283, 135-142	11.7	15
254	Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. *ACS Medicinal Chemistry Letters*, **2012**, 3, 715-720	4.3	15
253	Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor. *Biochemical Pharmacology*, **2013**, 85, 1171-81	6	15
252	Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 8003-11	3.4	15
251	Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1612-6	2.9	15
250	Extracellular adenine nucleotides regulate Na+/H+ exchanger NHE3 activity in A6-NHE3 transfectants by a cAMP/PKA-dependent mechanism. *Journal of Membrane Biology*, **2002**, 188, 249-59	2.3	15
249	Molecular recognition at adenine nucleotide (P2) receptors in platelets. *Seminars in Thrombosis and Hemostasis*, **2005**, 31, 205-16	5.3	15
248	Activation of Phosphoinositide Breakdown and Elevation of Intracellular Calcium in a Rat RBL-2H3 Mast Cell Line by Adenosine Analogs: Involvement of A(3)-Adenosine Receptors?. *Drug Development Research*, **1996**, 39, 36-46	5.1	15
247	Functionalized congener approach for the design of novel muscarinic agents. Synthesis and pharmacological evaluation of N-methyl-N-[4-(1-pyrrolidinyl)-2-butynyl] amides. *Journal of Medicinal Chemistry*, **1990**, 33, 741-8	8.3	15
246	Adenosine A-A Receptor-Receptor Interaction: Contribution to Guanosine-Mediated Effects. *Cells*, **2019**, 8,	7.9	15
245	Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets. *Biochemical Pharmacology*, **2021**, 187, 114311	6	15
244	Preclinical Evaluation of the First Adenosine A Receptor Partial Agonist Radioligand for Positron Emission Tomography Imaging. *Journal of Medicinal Chemistry*, **2018**, 61, 9966-9975	8.3	15
243	Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands. *Neuropharmacology*, **2015**, 98, 58-67	5.5	14
242	Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y receptor. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4733-4739	2.9	14
241	John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors. *Computational and Structural Biotechnology Journal*, **2015**, 13, 286-98	6.8	14
240	Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y Receptor Agonists. *MedChemComm*, **2017**, 8, 1897-1908	5	14

239	Polypharmacology of conformationally locked methanocarba nucleosides. *Drug Discovery Today*, **2017**, 22, 1782-1791	8.8	14
238	Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element. *ACS Medicinal Chemistry Letters*, **2011**, 2, 626-631	4.3	14
237	Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists. *Journal of Medicinal Chemistry*, **2008**, 51, 2088-99	8.3	14
236	Partial agonists for A(3) adenosine receptors. *Current Topics in Medicinal Chemistry*, **2004**, 4, 855-62	3	14
235	Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4851-4	2.9	14
234	In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X(2) receptors. *Journal of the Autonomic Nervous System*, **2000**, 81, 152-7		14
233	Selective A(3) adenosine receptor antagonists: water-soluble 3, 5-diacyl-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors. *Journal of Medicinal Chemistry*, **1999**, 42, 4232-8	8.3	14
232	Molecular probes for muscarinic receptors: functionalized congeners of selective muscarinic antagonists. *Life Sciences*, **1995**, 56, 823-30	6.8	14
231	Purine Functionalized Congeners as Molecular Probes for Adenosine Receptors. *Nucleosides & Nucleotides*, **1991**, 10, 1029-1038		14
230	Purinergic signaling in diabetes and metabolism. *Biochemical Pharmacology*, **2021**, 187, 114393	6	14
229	Thermostabilization and purification of the human dopamine transporter (hDAT) in an inhibitor and allosteric ligand bound conformation. *PLoS ONE*, **2018**, 13, e0200085	3.7	14
228	Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. *Journal of Medicinal Chemistry*, **2017**, 60, 3109-3123	8.3	13
227	Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor. *ACS Medicinal Chemistry Letters*, **2014**, 5, 1043-8	4.3	13
226	AMP-activated protein kinase as regulator of P2Y(6) receptor-induced insulin secretion in mouse pancreatic β-cells. *Biochemical Pharmacology*, **2013**, 85, 991-8	6	13
225	Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2010**, 333, 920-8	4.7	13
224	Discovery of New Human A(2A) Adenosine Receptor Agonists: Design, Synthesis, and Binding Mode of Truncated 2-Hexynyl-4'-thioadenosine. *ACS Medicinal Chemistry Letters*, **2010**, 2010, 516-520	4.3	13
223	Synthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor. *Purinergic Signalling*, **2009**, 5, 31-7	3.8	13
222	Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors. *Purinergic Signalling*, **2009**, 5, 39-50	3.8	13

221	Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. *Life Sciences*, **1997**, 61, PL75-80	6.8	13
220	Probing the binding site of the A1 adenosine receptor reengineered for orthogonal recognition by tailored nucleosides. *Biochemistry*, **2007**, 46, 7437-48	3.2	13
219	Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization. *Bioconjugate Chemistry*, **2002**, 13, 1100-11	6.3	13
218	Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors. *Bioconjugate Chemistry*, **1999**, 10, 667-77	6.3	13
217	Presence of both A1 and A2a adenosine receptors in human cells and their interaction. *Biochemical and Biophysical Research Communications*, **1995**, 208, 871-8	3.4	13
216	Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors. *European Journal of Pharmacology*, **1995**, 283, 185-92	5.3	13
215	Molecular probes for muscarinic receptors: derivatives of the M1-antagonist telenzepine. *Bioconjugate Chemistry*, **1992**, 3, 234-40	6.3	13
214	Molecular Characterization of A(1) and A(2a) Adenosine Receptors. *Drug Development Research*, **1993**, 28, 226-231	5.1	13
213	Effects of combinations of methylxanthines and adenosine analogs on locomotor activity in control and chronic caffeine-treated mice. *Drug Development Research*, **1993**, 30, 104-110	5.1	13
212	[(3)H]XAC (xanthine amine congener) is a radioligand for A(2)-adenosine receptors in rabbit striatum. *Neurochemistry International*, **1991**, 18, 207-13	4.4	13
211	Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors. *FEBS Letters*, **1987**, 225, 97-102	3.8	13
210	Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. *Journal of Medicinal Chemistry*, **1987**, 30, 1529-32	8.3	13
209	Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT/5HT Serotonin Receptor Antagonists. *Journal of Medicinal Chemistry*, **2016**, 59, 11006-11026	8.3	13
208	Design and in Vivo Characterization of A Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. *Journal of Medicinal Chemistry*, **2019**, 62, 1502-1522	8.3	13
207	Ligand design by targeting a binding site water. *Chemical Science*, **2020**, 12, 960-968	9.4	13
206	Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y and P2Y receptors. *Scientific Reports*, **2018**, 8, 8084	4.9	13
205	Inherited dysfunctional platelet P2Y receptor mutations associated with bleeding disorders. *Hamostaseologie*, **2016**, 36, 279-283	1.9	12
204	Activation of adenosine A or A receptors causes hypothermia in mice. *Neuropharmacology*, **2018**, 139, 268-278	5.5	12

203	Synthesis and P2Y receptor agonist activities of uridine 5'-phosphonate analogues. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 2304-15	3.4	12
202	Design, synthesis, and binding of homologated truncated 4'-thioadenosine derivatives at the human A3 adenosine receptors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 7015-21	3.4	12
201	Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor. *Biochemical Pharmacology*, **2010**, 80, 188-96	6	12
200	Activation and Desensitization of Rat A-Adenosine Receptors by Selective Adenosine Derivatives and Xanthine-7-Ribosides. *Drug Development Research*, **1998**, 44, 97-105	5.1	12
199	Synthesis of enantiomerically pure (S)-methanocarbaribo uracil nucleoside derivatives for use as antiviral agents and P2Y receptor ligands. *Journal of Organic Chemistry*, **2008**, 73, 8085-8	4.2	12
198	New 8-substituted xanthiene derivatives as potent bronchodilators. *Il Farmaco*, **2005**, 60, 974-80		12
197	Synthesis of hypermodified adenosine derivatives as selective adenosine A3 receptor ligands. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 1403-12	3.4	12
196	Nucleoside modification and concerted mutagenesis of the human A3 adenosine receptor to probe interactions between the 2-position of adenosine analogs and Gln167 in the second extracellular loop. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 1507-17	1.4	12
195	Affinity chromatography of the bovine cerebral cortex A1 adenosine receptor. *FEBS Letters*, **1989**, 257, 292-6	3.8	12
194	Muscarinic receptor binding and activation of second messengers by substituted N-methyl-N-[4-(1-azacycloalkyl)-2-butynyl]acetamides. *Journal of Medicinal Chemistry*, **1991**, 34, 1073-9	8.3	12
193	Autoradiographic localization of adenosine A1 receptors in rat brain using [3H]XCC, a functionalized congener of 1,3-dipropylxanthine. *Neuroscience Letters*, **1987**, 81, 69-74	3.3	12
192	Lung injury after in vivo reperfusion: outcome at 27 hours after reperfusion. *Anesthesiology*, **2008**, 109, 269-78	4.3	12
191	Exploration of Alternative Scaffolds for P2Y Receptor Antagonists Containing a Biaryl Core. *Journal of Medicinal Chemistry*, **2020**, 63, 9563-9589	8.3	12
190	Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design. *Methods in Molecular Biology*, **2018**, 1705, 45-72	1.4	12
189	Metabolic mapping of A3 adenosine receptor agonist MRS5980. *Biochemical Pharmacology*, **2015**, 97, 215-23	6	11
188	P2Y Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1281-1286	4.3	11
187	Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists. *Journal of Medicinal Chemistry*, **2016**, 59, 3249-63	8.3	11
186	Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 357, 24-35	4.7	11

185	Signaling of the Human P2Y(1) Receptor Measured by a Yeast Growth Assay with Comparisons to Assays of Phospholipase C and Calcium Mobilization in 1321N1 Human Astrocytoma Cells. *Purinergic Signalling*, **2005**, 1, 241-7	3.8	11
184	Improvement of cold tolerance by selective A1 adenosine receptor antagonists in rats. *Pharmacology Biochemistry and Behavior*, **1990**, 37, 107-12	3.9	11
183	Purine receptors: GPCR structure and agonist design. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2004**, 4, 337-47		11
182	Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels. *Pain*, **2020**, 161, 2179-2190	8	11
181	Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10. *Journal of Clinical Investigation*, **2021**, 131,	15.9	11
180	A1 Adenosine Receptor Agonists, Antagonists, and Allosteric Modulators **2018**, 59-89		10
179	4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y receptor. *MedChemComm*, **2013**, 4, 1156-1165	5	10
178	Bitopic fluorescent antagonists of the A adenosine receptor based on pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidin-5-amine functionalized congeners. *MedChemComm*, **2017**, 8, 1659-1667	5	10
177	Nucleoside conjugates of quantum dots for characterization of G protein-coupled receptors: strategies for immobilizing A2A adenosine receptor agonists. *Journal of Nanobiotechnology*, **2010**, 8, 11	9.4	10
176	Regulation of A1 adenosine receptors by amiodarone and electrical stimulation in rat myocardial cells in vitro. *Biochemical Pharmacology*, **1997**, 54, 583-7	6	10
175	Effects of Soil Sample Grinding Intensity on Carbon Determination by High-Temperature Combustion. *Communications in Soil Science and Plant Analysis*, **2007**, 38, 1733-1739	1.5	10
174	Barrier qualities of the mouse eye to topically applied drugs. *Experimental Eye Research*, **2007**, 85, 105-12	3.7	10
173	Adenosine A1 and A3 receptors: Distinct cardioprotection. *Drug Development Research*, **2001**, 52, 366-378	3.1	10
172	In Silico Drug Design for Purinergic GPCRs: Overview on Molecular Dynamics Applied to Adenosine and P2Y Receptors. *Biomolecules*, **2020**, 10,	5.9	9
171	Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A Receptor Agonists. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1935-1941	4.3	9
170	Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A Adenosine Receptors: Affinity Enhancement by -(2-Phenylethyl) Substitution. *Journal of Medicinal Chemistry*, **2020**, 63, 4334-4348	8.3	9
169	P2X4 receptor-eNOS signaling pathway in cardiac myocytes as a novel protective mechanism in heart failure. *Computational and Structural Biotechnology Journal*, **2015**, 13, 1-7	6.8	9
168	Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition. *Bioconjugate Chemistry*, **2012**, 23, 232-47	6.3	9

167	Caged agonist of P2Y1 and P2Y12 receptors for light-directed facilitation of platelet aggregation. *Biochemical Pharmacology*, **2008**, 75, 1341-7	6	9
166	Shift in purine/pyrimidine base recognition upon exchanging extracellular domains in P2Y 1/6 chimeric receptors. *Biochemical Pharmacology*, **2004**, 68, 2075-86	6	9
165	Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds. *Drug Development Research*, **2000**, 51, 151-158	5.1	9
164	Pyran Template Approach to the Design of Novel A Adenosine Receptor Antagonists. *Drug Development Research*, **1999**, 48, 171-177	5.1	9
163	Apparent heterogeneity of cardiac A1 adenosine receptors as revealed by radioligand binding experiments on N-ethylmaleimide-treated membranes. *Naunyn-Schmiedebergis Archives of Pharmacology*, **1991**, 344, 639-44	3.4	9
162	Electrochemical detection of biogenic amines following acylation by N-hydroxysuccinimide esters. *FEBS Letters*, **1985**, 188, 307-11	3.8	9
161	Species differences and mechanism of action of A adenosine receptor allosteric modulators. *Purinergic Signalling*, **2018**, 14, 59-71	3.8	9
160	Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 967	6.8	8
159	Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs. *Cells*, **2020**, 9,	7.9	8
158	A binding kinetics study of human adenosine A receptor agonists. *Biochemical Pharmacology*, **2018**, 153, 248-259	6	8
157	Crystal structures of the A adenosine receptor and their use in medicinal chemistry. *In Silico Pharmacology*, **2013**, 1, 22	4.3	8
156	Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y receptor-mediated platelet aggregation. *Thrombosis and Haemostasis*, **2012**, 108, 119-32	7	8
155	Adenosine Receptors: The Contributions by John W. Daly. *Heterocycles*, **2009**, 79, 73-83	0.8	8
154	The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia. *Journal of Thrombosis and Thrombolysis*, **2007**, 24, 115-22	5.1	8
153	Northern Ring Conformation of Methanocarba-Adenosine 5'-Triphosphate Required for Activation of P2X Receptors. *Drug Development Research*, **2004**, 61, 227-232	5.1	8
152	New high-performance liquid chromatographic procedure for the detection and quantification of beta-phenylethylamine. *Biomedical Applications*, **1987**, 415, 124-8		8
151	Adenosine A3 Receptors in Muscle Protection **2010**, 257-280		8
150	Probing structure-activity relationship in arrestin2 recruitment of diversely substituted adenosine derivatives. *Biochemical Pharmacology*, **2018**, 158, 103-113	6	8

149	Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. *ACS Omega*, **2018**, 3, 12658-12678	3.9	8
148	Radioligand Binding Assays for Adenosine Receptors **1990**, 17-55		8
147	Molecular Biology and Pharmacology of Recombinant Adenosine Receptors. *Developments in Cardiovascular Medicine*, **1998**, 1-20		8
146	Discovery and Structure-Activity Relationships of Novel Template, Truncated 1'-Homologated Adenosine Derivatives as Pure Dual PPAR/ Modulators. *Journal of Medicinal Chemistry*, **2020**, 63, 16012-16027	8.3	7
145	Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3302-6	2.9	7
144	Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles. *Purinergic Signalling*, **2013**, 9, 183-98	3.8	7
143	Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches. *MedChemComm*, **2013**, 2013, 619-630	5	7
142	NEW BASE-ALTERED ADENOSINE ANALOGUES: SYNTHESIS AND AFFINITY AT ADENOSINE A and A RECEPTORS. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 3085-3090	2.9	7
141	Versatile Synthesis of 6-Alkyl and Aryl Substituted Pyridoxal Derivatives. *Synthesis*, **2000**, 2000, 119-122	2.9	7
140	P-Purinoceptors: Advances and therapeutic opportunities. *Expert Opinion on Investigational Drugs*, **1995**, 4, 925-934	5.9	7
139	8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine Receptors. *Drug Development Research*, **1993**, 29, 292-298	5.1	7
138	Acute treatment of mice with high doses of caffeine: An animal model for choreiform movement. *Drug Development Research*, **1993**, 30, 121-128	5.1	7
137	N6-functionalized congeners of adenosine with high potency at A2-adenosine receptors: potential ligands for affinity chromatography. *Biochemical and Biophysical Research Communications*, **1986**, 136, 1097-102	3.4	7
136	Nucleoside-based A3 adenosine receptor antagonists as drug candidates. *Drugs of the Future*, **2009**, 34, 43	2.3	7
135	Design and in vivo activity of A adenosine receptor agonist prodrugs. *Purinergic Signalling*, **2020**, 16, 367-387	3.8	7
134	Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design. *ChemMedChem*, **2020**, 15, 1958-1973	3.7	7
133	Structure-Activity Relationship of Heterocyclic P2Y Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres. *Journal of Medicinal Chemistry*, **2021**, 64, 5099-5122	8.3	7
132	A adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states. *Journal of Computer-Aided Molecular Design*, **2019**, 33, 983-996	4.2	7

131	P2 Receptor Modeling and Identification of Ligand Binding Sites **1998**, 135-166		7
130	International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.. *Pharmacological Reviews*, **2022**, 74, 340-372	22.5	7
129	Allosteric Antagonism of the A Adenosine Receptor by a Series of Bitopic Ligands. *Cells*, **2020**, 9,	7.9	6
128	Regio- and stereoselective synthesis of truncated 3'-aminocarbanucleosides and their binding affinity at the A3 adenosine receptor. *Organic and Biomolecular Chemistry*, **2011**, 9, 6955-62	3.9	6
127	Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors. *Nucleosides, Nucleotides and Nucleic Acids*, **2006**, 25, 1425-36	1.4	6
126	Ribose modified nucleosides and nucleotides as ligands for purine receptors. *Nucleosides, Nucleotides and Nucleic Acids*, **2001**, 20, 333-41	1.4	6
125	Probing adenosine receptors using biotinylated purine derivatives. *Methods in Enzymology*, **1990**, 184, 668-71	1.7	6
124	Nucleotide P2Y receptor agonists are in vitro and in vivo prodrugs of A/A adenosine receptor agonists: implications for roles of P2Y and A/A receptors in physiology and pathology. *Purinergic Signalling*, **2020**, 16, 543-559	3.8	6
123	Adenosine A Receptors Are Upregulated in Peripheral Blood Mononuclear Cells from Atrial Fibrillation Patients. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
122	Structure Activity Relationships of P2 Receptor Agonists and Antagonists **1998**, 81-107		6
121	Evidence for the Interaction of A Adenosine Receptor Agonists at the Drug-Binding Site(s) of Human P-glycoprotein (ABCB1). *Molecular Pharmacology*, **2019**, 96, 180-192	4.3	5
120	Medicinal Chemistry of the A3 Adenosine Receptor **2018**, 169-198		5
119	Synthesis and evaluation of N-substituted apioadenosines as potential adenosine A receptor modulators. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 4257-68	3.4	5
118	Engineering of A3 adenosine and P2Y nucleotide receptors and their ligands. *Drug Development Research*, **2003**, 58, 330-339	5.1	5
117	Probing adenosine and P2 receptors: Design of novel purines and nonpurines as selective ligands. *Drug Development Research*, **2001**, 52, 178-186	5.1	5
116	Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding. *Archives of Biochemistry and Biophysics*, **1993**, 305, 611-7	4.1	5
115	High affinity acylating antagonists for muscarinic receptors. *Life Sciences*, **1992**, 51, 345-51	6.8	5
114	TRIFUNCTIONAL LIGANDS: A RADIOIODINATED HIGH AFFINITY ACYLATING ANTAGONIST FOR THE A ADENOSINE RECEPTOR. *Pharmacology Communications*, **1992**, 1, 145-154		5

113	P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	5
112	Synthesis and Binding Affinity of Homologated Adenosine Analogues as A Adenosine Receptor Ligands. *Bulletin of the Korean Chemical Society*, **2011**, 32, 1620-1624	1.2	5
111	Conjugable A adenosine receptor antagonists for the development of functionalized ligands and their use in fluorescent probes. *European Journal of Medicinal Chemistry*, **2020**, 186, 111886	6.8	5
110	Adipocyte P2Y14 receptors play a key role in regulating whole-body glucose and lipid homeostasis. *JCI Insight*, **2021**, 6,	9.9	5
109	Purinergic Signaling in Liver Pathophysiology. *Frontiers in Endocrinology*, **2021**, 12, 718429	5.7	5
108	Probing GPCR structure: adenosine and P2Y nucleotide receptors. *Methods in Enzymology*, **2013**, 520, 199-217	1.7	4
107	Effects of theophylline and dibutyryl-cAMP on adenosine receptors and heart rate in cultured cardiocytes. *Journal of Basic and Clinical Physiology and Pharmacology*, **1996**, 7, 347-62	1.6	4
106	Chapter 13. A Adenosine Receptors. *Annual Reports in Medicinal Chemistry*, **2003**, 38, 121-130	1.6	4
105	Two distinct P2Y receptors are involved in purine- and pyrimidine-evoked Ca2+ elevation in mammalian brain astrocytic cultures. *Drug Development Research*, **2001**, 52, 122-132	5.1	4
104	Structurally related nucleotides as selective agonists and antagonists at P2Y1 receptors. *Il Farmaco*, **2001**, 56, 71-5		4
103	Uptake of glucose analogs reflects the rate of contraction of cultured myocytes. *Journal of Basic and Clinical Physiology and Pharmacology*, **1999**, 10, 287-303	1.6	4
102	RADIOLABELING AND EFFICIENT SYNTHESIS OF TRITIATED 2-CHLORO--(3-IODOBENZYL)ADENOSINE-5'--METHYLURON-AMIDE, A POTENT, SELECTIVE A ADENOSINE RECEPTOR AGONIST. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1996**, 38, 547-560	1.9	4
101	Characterization of catecholamine-polypeptide conjugates. *European Polymer Journal*, **1983**, 19, 997-1004	3.2	4
100	NUCLEOSIDE PRODRUGS OF A ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS. *Collection of Czechoslovak Chemical Communications*, **2006**, 71, 912-928		4
99	Prevention and rescue of cardiac dysfunction by methanocarba adenosine monophosphonate derivatives. *Purinergic Signalling*, **2020**, 16, 61-72	3.8	4
98	Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1. *Journal of Medicinal Chemistry*, **2020**, 63, 14087-14117	8.3	4
97	Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A Receptor Subtype. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
96	Pyrazolo[4,3-][1,2,4]triazolo[1,5-]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example. *MedChemComm*, **2019**, 10, 1094-1108	5	4

95	Novel ATP Agonists Reveal Receptor Heterogeneity Within P2X and P2Y Subtypes **1995**, 149-156		4
94	Behavioral Effects of Adenosine Receptor stimulation **1995**, 489-498		4
93	A2A Adenosine Receptor: Structures, Modeling, and Medicinal Chemistry **2018**, 91-136		3
92	Rapid synthesis of alkoxyamine hydrochloride derivatives from alkyl bromide and di--butoxycarbonylhydroxylamine ((Boc)NOH). *Synthetic Communications*, **2014**, 44, 2344-2347	1.7	3
91	Riboflavin: Inhibitory Effects on Receptors, G-Proteins, and Adenylate Cyclase. *Drug Development Research*, **1997**, 42, 98-108	5.1	3
90	Design and synthesis of A3 adenosine receptor ligands, 2'-fluoro analogues of Cl-IB-MECA. *Nucleosides, Nucleotides and Nucleic Acids*, **2003**, 22, 927-30	1.4	3
89	Purification and Recognition of Recombinant Mouse P2X(1) Receptors Expressed in a Baculovirus System. *Drug Development Research*, **2000**, 51, 7-19	5.1	3
88	Synthesis and adenosine receptor affinity of 7-beta-D-ribofuranosylxanthine. *Nucleosides & Nucleotides*, **1998**, 17, 759-68		3
87	Induction of Apoptosis in HL-60 Human Promyelocytic Leukemia Cells by Adenosine A3Receptor Agonists. *Biochemical and Biophysical Research Communications*, **1996**, 221, 849	3.4	3
86	APEC, An A2-Selective Adenosine Agonist, is a More Potent Locomotor Depressant Than N6-Cyclohexyladenosine. *Nucleosides & Nucleotides*, **1991**, 10, 1211-1212		3
85	Muscarinic receptor probes based on amine congeners of pirenzepine and telenzepine. *Bioorganic and Medicinal Chemistry Letters*, **1992**, 2, 845-850	2.9	3
84	Californium-252 plasma desorption mass spectrometry as an aid in the synthesis of a series of adenosine and xanthine conjugates. *Journal of the Chemical Society Perkin Transactions 1*, **1986**, 2143		3
83	Photochemically induced nuclear polarization probes for thiol groups in peptides and proteins. *Journal of the Chemical Society Chemical Communications*, **1983**, 1384		3
82	Visual methods for the nanomolar detection of electrophilic reagents. *Journal of Proteomics*, **1983**, 8, 213-22		3
81	Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors. *Medicinal Chemistry*, **2019**, 15, 863-872	1.8	3
80	Adenosine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. *IUPHAR/BPS Guide To Pharmacology CITE*, **2019**, 2019,	1.7	3
79	Structure activity relationship of novel antiviral nucleosides against Enterovirus A71. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127599	2.9	3
78	Biological Evaluation of 5'-(-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors. *ACS Medicinal Chemistry Letters*, **2021**, 12, 373-379	4.3	3

77	UDP-glucose and P2Y14 receptor amplify allergen-induced airway eosinophilia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	3
76	Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition. *European Journal of Medicinal Chemistry*, **2021**, 212, 113125	6.8	3
75	Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A adenosine receptor antagonists. *MedChemComm*, **2018**, 9, 1920-1932	5	3
74	Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary. *Journal of Medicinal Chemistry*, **2021**, 64, 12525-12536	8.3	3
73	Preface: special issue on medicinal chemistry of purines. *Purinergic Signalling*, **2009**, 5, 1	3.8	2
72	Adenosine receptor subtypes and cardioprotection. *Drug Development Research*, **1998**, 45, 394-401	5.1	2
71	Synthesis of 3'-acetamidoadenosine derivatives as potential A3 adenosine receptor agonists. *Nucleosides, Nucleotides and Nucleic Acids*, **2008**, 27, 408-20	1.4	2
70	Design and synthesis of truncated 4'-thioadenosine derivatives as potent and selective A3 adenosine receptor antagonists. *Nucleic Acids Symposium Series*, **2008**, 641-2		2
69	Synthesis of N6-substituted 3'-ureidoadenosine derivatives as highly potent agonists at the mutant A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 717-9	1.4	2
68	Design and synthesis of A3 adenosine receptor ligands, 3'-fluoro analogues of Cl-IB-MECA. *Nucleosides, Nucleotides and Nucleic Acids*, **2003**, 22, 923-5	1.4	2
67	Synthesis of 3'-ureidoadenosine analogues and their binding affinity to the A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 1119-21	1.4	2
66	Synthesis of tritiated functionalized congeners of 1.3-dipropylxanthine having high affinity at adenosine receptors. *Journal of Labelled Compounds and Radiopharmaceuticals*, **1986**, 23, 519-526	1.9	2
65	A adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. *European Journal of Medicinal Chemistry*, **2021**, 113983	6.8	2
64	Structure and Function of G Protein-Coupled Receptors Studied Using Sequence Analysis, Molecular Modeling and Receptor Engineeri **2012**, 63-79		2
63	John W. Daly - An Appreciation. *Heterocycles*, **2009**, 79, 61-71	0.8	2
62	Fragment-based design of selective GPCR ligands guided by free energy simulations. *Chemical Communications*, **2021**, 57, 12305-12308	5.8	2
61	Pharmacological characterization of DPTN and other selective A adenosine receptor antagonists. *Purinergic Signalling*, **2021**, 1	3.8	2
60	Spinal A adenosine receptor activation acutely restores morphine antinociception in opioid tolerant male rats. *Journal of Neuroscience Research*, **2021**,	4.4	2

59	Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 41, 128008	2.9	2
58	Survey of ribose ring pucker of signaling nucleosides and nucleotides. *Nucleosides, Nucleotides and Nucleic Acids*, **2020**, 39, 322-341	1.4	2
57	Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets. *RSC Medicinal Chemistry*, **2021**, 12, 1808-1825	3.5	2
56	Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines. *ACS Pharmacology and Translational Science*, **2021**, 4, 680-686	5.9	2
55	Structure-activity relationships of pyrimidine nucleotides containing a 5'-□methylene diphosphonate at the P2Y receptor. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 45, 128137	2.9	2
54	Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors **2000**, 49, 253		2
53	Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics. *ACS Pharmacology and Translational Science*, **2020**, 3, 190-202	5.9	1
52	Activation of basal forebrain purinergic P2 receptors promotes wakefulness in mice. *Scientific Reports*, **2018**, 8, 10730	4.9	1
51	Synthesis of 2-chloro-N6-substituted-4'-thioadenosine-5'-N, N-dialkyluronamides as potent and selective A3 adenosine receptor antagonists. *Nucleic Acids Symposium Series*, **2008**, 645-6		1
50	Stereoselective synthesis of 1'-functionalized-4'-thionucleosides. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 1011-4	1.4	1
49	D-4'-thioadenosine derivatives as highly potent and selective agonists at the human A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2005**, 24, 607-9	1.4	1
48	Molecular recognition in P2 nucleotide receptors. *Nucleic Acids Symposium Series*, **2003**, 3-4		1
47	An adenosine A3 receptor-selective agonist does not modulate calcium-activated potassium currents in hippocampal CA1 pyramidal neurons. *Progress in Brain Research*, **1999**, 120, 275-85	2.9	1
46	Liquid chromatographic assay for cerebrospinal fluid normetanephrine. *Life Sciences*, **1987**, 40, 1513-21	6.8	1
45	PHOTOLABILE A-ADENOSINE RECEPTOR AGONISTS AS "CAGED" ELECTROPHYSIOLOGICAL PROBES. *Medicinal Chemistry Research*, **1991**, 1, 322-329	2.2	1
44	History of Chemistry in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). *Bulletin for the History of Chemistry*, **2014**, 39, 150-165		1
43	280-LB: Role of A1 and A3 Adenosine Receptors in Whole Body Glucose Metabolism. *Diabetes*, **2019** , 68, 280-LB	0.9	1
42	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms. *PLoS ONE*, **2020**, 15, e0243986	3.7	1

41	A3 Adenosine Receptor Agonists: History and Future Perspectives **2010**, 93-120		1
40	Lack of Adipocyte Purinergic P2Y6 Receptor Greatly Improves Whole Body Glucose Homeostasis		1
39	A Functionalized Congener Approach to Muscarinic Ligands. *Advances in Behavioral Biology*, **1989**, 1-9		1
38	Adenosine Metabotropic Receptors in Chronic Pain Management. *Frontiers in Pharmacology*, **2021**, 12, 651038	5.6	1
37	Tribute to Prof. Geoffrey Burnstock: transition of purinergicsignaling to drug discovery. *Purinergic Signalling*, **2021**, 17, 3-8	3.8	1
36	Optical control of adenosine A receptor function in psoriasis. *Pharmacological Research*, **2021**, 170, 105731	10.2	1
35	Adenosine A receptor is dispensable for hepatocyte glucose metabolism and insulin sensitivity. *Biochemical Pharmacology*, **2021**, 192, 114739	6	1
34	Synthesis and evaluation of adenosine derivatives as A, A, A and A adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A agonists. *European Journal of Medicinal Chemistry*, **2021**, 223, 113607	6.8	1
33	Activation of phosphoinositide breakdown and elevation of intracellular calcium in a rat RBL-2H3 mast cell line by adenosine analogs: Involvement of A3-adenosine receptors? **1996**, 39, 36		1
32	Design, synthesis, and anti-tumor activity of 4'-thionucleosides as potent and selective agonists at the human A3 adenosine receptor. *Nucleosides, Nucleotides and Nucleic Acids*, **2007**, 26, 1565-8	1.4	0
31	Interaction of A adenosine receptor ligands with the human multidrug transporter ABCG2.. *European Journal of Medicinal Chemistry*, **2022**, 231, 114103	6.8	0
30	Targeting the A adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice.. *Acta Neuropathologica Communications*, **2022**, 10, 11	7.3	0
29	New Synthetic Approach to the Bicyclo[3.1.0]hexane Ring System from (+)-(1,4)-4-(Benzyloxymethyl)-4-(hydroxymethyl)cyclopent-2-enol. *Bulletin of the Korean Chemical Society*, **2005**, 26, 1503-1504	1.2	0
28	Convergent synthesis of 2-thioether-substituted ()-methanocarba-adenosines as purine receptor agonists.. *RSC Advances*, **2021**, 11, 27369-27380	3.7	0
27	Discovery of Highly Potent Adenosine A Receptor Agonists: Targeting Positron Emission Tomography Probes. *ACS Chemical Neuroscience*, **2021**, 12, 3410-3417	5.7	0
26	Selective A Adenosine Receptor Antagonist Radioligand for Human and Rodent Species.. *ACS Medicinal Chemistry Letters*, **2022**, 13, 623-631	4.3	0
25	Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets.. *Current Opinion in Pharmacology*, **2022**, 63, 102190	5.1	0
24	Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A adenosine receptor antagonists.. *Biochemical Pharmacology*, **2022**, 200, 115027	6	0

23	Optical Control of Adenosine A Receptor Signaling: Towards a Multimodal Phototherapy in Psoriasis?. *Frontiers in Immunology*, **2022**, 13, 904762	8.4	0
22	Adenosine ? **2017**,		
21	A Key Opinion Leader interview: insight into the research and career of Dr KA Jacobson. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 125-9	6.8	
20	The therapeutic effect of 2-cyclohexylthio-AMP in heart failure. *Journal of Cardiovascular Pharmacology*, **2013**, 61, 553-9	3.1	
19	Modified Nucleosides as Selective Modulators of Adenosine Receptors for Therapeutic Use433-449		
18	Chapter 8. Purine and pyrimidine nucleotide (P2) receptors. *Annual Reports in Medicinal Chemistry*, **2002**, 37, 75-84	1.6	
17	Seizures induced by methylxanthines, potential cognitive enhancers in dementia syndromes. *Journal of Neural Transmission Parkinsonis Disease and Dementia Section*, **1989**, 1, 45-45		
16	Identification and Characterization of Biased A3 Adenosine Receptor Allosteric Modulators. *FASEB Journal*, **2020**, 34, 1-1	0.9	
15	Purinergic GPCR transmembrane residues involved in ligand recognition and dimerization. *Methods in Cell Biology*, **2021**, 166, 133-159	1.8	
14	UDP is an antagonist at the hP2Y14 receptor. *FASEB Journal*, **2007**, 21, A424	0.9	
13	Identification of distinct, ligand-specific structural changes in a G protein-coupled receptor. *FASEB Journal*, **2007**, 21, A425	0.9	
12	The glucose moiety of uridine 5? diphosphoglucose is structurally permissive in activation of the human P2Y14 receptor. *FASEB Journal*, **2008**, 22, 720.10	0.9	
11	Polymorphic Role of P2Y6 Receptor in Insulin Sensitive Organs Adipose Tissue and Skeletal Muscle. *Diabetes*, **2018**, 67, 1769-P	0.9	
10	Regulation of adenosine receptors in cultured heart cells. *Advances in Experimental Medicine and Biology*, **1995**, 382, 205-15	3.6	
9	Molecular Modeling and Reengineering of A3 Adenosine Receptors **2010**, 149-161		
8	Geoffrey Burnstock - An accidental pharmacologist. *Biochemical Pharmacology*, **2021**, 187, 114300	6	
7	Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor **2021**, 184-196		
6	Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986		

5 Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986

4 Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986

3 Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986

2 Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986

1 Activation of neuronal adenosine A1 receptors causes hypothermia through central and peripheral mechanisms **2020**, 15, e0243986